Anti-HPV vaccination: A review of recent economic data for Italy

F. S. Mennini, S. Costa, G. Favato, M. Picardo

Research output: Contribution to journalArticlepeer-review


The total cost of HPV-related diseases accounts for €200-250 million of which €210 million is absorbed by the prevention and treatment of precancerous lesions and cervical cancer. Although both available HPV vaccines are below the threshold value for economic convenience (€9,569 and €26,361 per QALY-gained for the quadrivalent and bivalent vaccines, respectively), at this point in time long-term economic models developed for Italy seem to indicate the quadrivalent vaccine as the most cost-effective option. Recent publications by official bodies, including the World Health Organization and the Supervisory Authority for Public Contracts in Italy, recommend that the decision-making process be based on both the quality of goods and services as well as the best achievable price.

Original languageEnglish
Issue numberSUPPL. 1
Publication statusPublished - May 29 2009


  • Cost-effectiveness analysis
  • Economic evaluation
  • HPV vaccine
  • Italy

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine


Dive into the research topics of 'Anti-HPV vaccination: A review of recent economic data for Italy'. Together they form a unique fingerprint.

Cite this